---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-25-000007"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:12:16.558528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q4: PYRUKYND revenue $10.7M, mitapivat PDUFA Sept 7, 2025; cash $1.5B

## Summary
- PYRUKYND net revenue $10.7M in Q4 (+20% QoQ), full year $36.5M vs $26.8M in 2023.
- Filed for mitapivat approval in thalassemia in US, EU, KSA, UAE; PDUFA goal date Sept 7, 2025.
- Phase 3 RISE UP for sickle cell disease fully enrolled (>200 patients); topline results late 2025, potential launch 2026.
- Cash, cash equivalents and marketable securities $1.5B as of Dec 31, 2024; net loss Q4 $96.5M, full year net income $673.7M.
- Board member David Schenkein to step down effective Feb 28, 2025; remains as strategic advisor.

## SEC filing metadata
- accession: 0001439222-25-000007
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/0001439222-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000007/agio-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-25-000007
- JSON: https://secwatch.observer/filing/0001439222-25-000007.json
- Plain text: https://secwatch.observer/filing/0001439222-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.